Rifampicin and anti-hypertensive drugs in chronic kidney disease: Pharmacokinetic interactions and their clinical impact

Patients on dialysis have an increased incidence of tuberculosis (TB). Rifampicin, a first-line antitubercular therapy (ATT) drug, is a potent inducer of hepatic cytochrome P450 (CYP). There is potential for pharmacokinetic interaction between rifampicin and anti-hypertensives that are CYP substrate...

Descripción completa

Detalles Bibliográficos
Autores principales: Agrawal, A., Agarwal, S. K., Kaleekal, T., Gupta, Y. K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015508/
https://www.ncbi.nlm.nih.gov/pubmed/27795624
http://dx.doi.org/10.4103/0971-4065.176145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015508/
https://www.ncbi.nlm.nih.gov/pubmed/27795624
http://dx.doi.org/10.4103/0971-4065.176145

Ejemplares similares